General News

Catalio, formerly Nexus Division, Completes Spin Out from Camden Partners Holdings

BALTIMORE, MD – Catalio Capital Management, LP (“Catalio”) announced on June 24 the completion of its spin out from Camden Partners Holdings, LLC (“Camden”). Established as part of Camden in 2016, Catalio (formerly known as Nexus) is now an independent firm focused on investing in a diversified portfolio of biomedical technology companies founded by world-renowned, serial scientist-entrepreneurs. Going forward, Camden will not have any role in Catalio’s governance, but some Camden employees and partners will continue to be supportive limited partners of Catalio.

George Petrocheilos and R. Jacob Vogelstein will continue to lead Catalio and will serve as the firm’s Managing Partners. The key members of the Camden investment team formerly dedicated to the venture capital strategy will also become part of Catalio, ensuring continuity for portfolio companies, investors and advisers. This includes Tom V. Brooks, Partner and Investment Committee member, and Edward J. Mathias, Chairman. 

George Petrocheilos, Managing Partner, said, “Our move to independence represents the natural evolution of our business, which has built a track record of investing in a variety of breakthrough biomedical technology companies around the globe. Camden and its CEO, David Warnock, played a critical role in helping us create Nexus by providing the operating capital we needed to launch our first fund, and they have continued to support us over the past years as we have grown. We are grateful and thankful to David and Camden for the confidence and support they have shown and provided to us over the past four years.”

“The category-defining businesses in the life sciences have always been the companies that successfully paired the best science and the best people with the best investment partners,” said Dr. Vogelstein, Managing Partner. “I believe the unique composition of our team at Catalio allows us to identify the next generation of breakthrough biomedical technology companies and catalyze their development from inception through IPO.”  

About Catalio Capital Management, LP

Catalio Capital Management, LP (formerly known as Nexus) focuses on investing in breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics, and data-driven insights. Catalio’s Partners include twenty-five world-renowned scientists with extensive academic bona fides who have also started several successful companies based on their research. Catalio is a transliteration of the Greek verb for “catalyze” because we created the firm as a catalyst to accelerate the growth of our portfolio companies. 

More information is available on Catalio’s website: www.cataliocapital.com


UPPER DARBY, PA – The picturesque fairways of Llanerch Country Club in Havertown, PA, played host on June 10 to the Fourth Annual Golf Outing benefiting the St.

Top Stories


A pregnant woman was driving in the HOV lane near Dallas.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.


After Rare Flash Flood Emergency, Florida Prepares for More Heavy Rainfall in Coming Days

FORT LAUDERDALE, Fla. (AP) — A tropical disturbance has brought a rare flash flood emergency to much of southern Florida as residents prepared to weather more heavy rainfall on Thursday and Friday.

NICOSIA - Following Greece’s agreement with Egypt to take in as many as 10,000 seasonal workers for agricultural jobs, Cyprus will be getting 1000 after a deal was worked out at the International Labor Conference (ILC) held in Geneva.

WASHINGTON (AP) — Wholesale price increases fell in May, the latest sign that inflation pressures in the United States may be easing as the Federal Reserve considers a timetable for cutting interest rates.

BUENOS AIRES, Argentina (AP) — Lionel Messi won the World Cup in 2022, won the Copa America in 2021, and wants to show he has the hunger to win some more.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. [email protected]

You may unsubscribe at any time using the link in our newsletter.